Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilaria Scortechini

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
American Journal of Hematology|February 12, 2024
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM studyFrancesco Autore, Andrea Visentin, Marina Deodato, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2012
Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignanciesGiuseppe Messina, Luisa Giaccone, Moreno Festuccia, et al.
British Journal of Haematology|March 10, 2026
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana LinfomiGian Matteo Rigolin, Stefano Soddu, Riccardo Dondolin, et al.
Hematological Oncology|July 1, 2023
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia studyFrancesco Autore, Idanna Innocenti, Gianluigi Reda, et al.
Bone Marrow Transplantation|May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesPeter Dreger, Mauricette Michallet, Paul Bosman, et al.
Oncotarget|May 29, 2018
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphomaAlessandro Broccoli, Beatrice Casadei, Alice Morigi, et al.
Leukemia & Lymphoma|January 15, 2025
Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey)Michele Malagola, Luca Castagna, Mirko Farina, et al.
Cancers|March 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE StudyStefano Molica, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Leukemia|April 15, 2020
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL studyMassimo Gentile, Fortunato Morabito, Giovanni Del Poeta, et al.
Blood Cancer Journal|September 17, 2020
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximabMassimo Gentile, Enrica Antonia Martino, Andrea Visentin, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
American Journal of Hematology|February 12, 2024
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM studyFrancesco Autore, Andrea Visentin, Marina Deodato, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2012
Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignanciesGiuseppe Messina, Luisa Giaccone, Moreno Festuccia, et al.
British Journal of Haematology|March 10, 2026
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana LinfomiGian Matteo Rigolin, Stefano Soddu, Riccardo Dondolin, et al.
Hematological Oncology|July 1, 2023
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia studyFrancesco Autore, Idanna Innocenti, Gianluigi Reda, et al.
Bone Marrow Transplantation|May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesPeter Dreger, Mauricette Michallet, Paul Bosman, et al.
Oncotarget|May 29, 2018
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphomaAlessandro Broccoli, Beatrice Casadei, Alice Morigi, et al.
Leukemia & Lymphoma|January 15, 2025
Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey)Michele Malagola, Luca Castagna, Mirko Farina, et al.
Cancers|March 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE StudyStefano Molica, Potito Rosario Scalzulli, Lydia Scarfò, et al.
Leukemia|April 15, 2020
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL studyMassimo Gentile, Fortunato Morabito, Giovanni Del Poeta, et al.
Blood Cancer Journal|September 17, 2020
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximabMassimo Gentile, Enrica Antonia Martino, Andrea Visentin, et al.
Pageof 4